Finoriq research workspace
ALUMIS INC. (ALMS) SEC Filings & Filing Highlights
ALUMIS INC. offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of. Review ALMS SEC filings, filing highlights, and disclosure activity on Finoriq.
Company Snapshot
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.
- Company
- ALUMIS INC. (ALMS)
- Ticker
- ALMS
- Market Cap
- $3.6B
- Latest Price
- $28.3
- Industry
- Biotech & Pharma
ALUMIS INC. (ALMS) Recent SEC Filing Highlights
Recent SEC filings, filing events, and disclosure highlights indexed for ALUMIS INC. (ALMS).
| Event | Form | Date |
|---|---|---|
| On June 30, 2026, Alumis Inc. held its 2026 Annual Meeting of Stockholders. As of May 5, 2026,...On June 30, 2026, Alumis Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). As of May 5, 2026, the r... | 8-K5.07 | 2026-07-02 |
| 1 Transforming Immune-Mediated Disease Treatment with Precision Engineered TYK2 Inhibitors Corp...1 Transforming Immune-Mediated Disease Treatment with Precision Engineered TYK2 Inhibitors Corporate Deck: June 2026 | 8-K8.01 | 2026-06-29 |
| Alumis Reports First Quarter 2026 Financial Results and Highlights Recent AchievementsAlumis Reports First Quarter 2026 Financial Results and Highlights Recent Achievements | 8-K2.02 | 2026-05-14 |
| Envudeucitinib achieved robust PASI responses by Week 16, with significant continued improvemen...Alumis’ Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Tria... | 8-K8.01 | 2026-03-30 |
| Alumis Reports Year End 2025 Financial Results and HighlightsAlumis Reports Year End 2025 Financial Results and Highlights | 8-K2.02 | 2026-03-19 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.